Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 46

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 46
---
 are owners of MIRALOGX, the licensor to TELI and TELO of Telomir-1. In some cases, such licenses obligate TELI to pay royalties to MIRALOGX even if TELI is not then earning revenue on the licensed products.

The Amended and Restated Exclusive
License Agreement, dated August 11, 2023, pursuant to which TELO received rights in Telomir-1 in North America was between MIRALOGIX
and TELO. As described above, MIRALOGIX has substantial interests in TELI and in TELO, and it is the licensor in both the Telomir-1 rights
granted to TELO in North America and to TELI in the rest of the world.

The members of the TELO Board were aware of and considered these interests in evaluating the Merger and in making the TELO Recommendation. The interests of TELO’s directors and executive officers are described in more detail in “ Interests of the TELO Directors, Executive Officers and Affiliate Shareholders in the Merger”on page 34 of this proxy statement.

The completion of the Merger is not conditioned on the receipt of an opinion of counsel to the effect that the Merger will qualify for the Intended Tax Treatment, and neither TELO nor TELI intends to request a ruling from the Internal Revenue Service regarding the U.S. federal income tax consequences of the Merger.

It is intended that, for U.S. federal income tax purposes, the Merger will constitute the Intended Tax Treatment (as defined below). However, the completion of the Merger is not conditioned on the Merger qualifying for the Intended Tax Treatment or upon the receipt of an opinion from counsel to that effect, and whether or not the Transaction will qualify for the Intended Tax Treatment depends on facts that will not be known until the Merger is completed. Finally, neither TELO nor TELI intends to request a ruling from the Internal Revenue Service regarding the U.S. federal income tax consequences of the Merger. Therefore, even if TELO concludes that the Merger qualifies for the Intended Tax Treatment, no assurance can be given that the Internal Revenue Service will not challenge that conclusion or that a court would not sustain such a challenge.

You should read “ Material U.S. Federal Income Tax Considerations” and consult your own tax advisors regarding the U.S. federal income tax consequences of the Merger to you in your particular